Jul 2026
Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer.
This study elucidates a therapeutically targetable KPNB1-p65-Bcl-2 survival axis in multiple cancers and establishes a foundation for developing next-generation KPNB1 inhibitors.
Cong Li, Qiaohua Yan, Muhammad Muddasar Saeed et al.
· Cell Chemical Biology · 0 citations